<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05062031</url>
  </required_header>
  <id_info>
    <org_study_id>GMN_2021_11</org_study_id>
    <nct_id>NCT05062031</nct_id>
  </id_info>
  <brief_title>Myopia Control in Children: Comparison of Defocus Incorporated Multiple Segments® Lenses Versus Atropine 0.05% Eyedrops</brief_title>
  <acronym>ATROSMART</acronym>
  <official_title>Comparison of Defocus Incorporated Multiple Segments® (DIMS®) Lenses Alone Versus Monofocal Lenses + Atropine 0.05% Eyedrops on the Evolution of Ocular Axial Length at 2 Years in Myopia Control in Children: Single-centre Prospective Randomised Controlled 1:1 Open-label Non-inferiority Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HOYA Lamphun Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ecouter Voir</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Myopia is the most common refractive disorder in the world. Many strategies have been&#xD;
      developed to control myopia in children. Among them, the instillation of low-concentration&#xD;
      atropine eyedrops has been proven to be effective in numerous publications. Nevertheless, the&#xD;
      spreading of atropine use is limited by: (1) its uneven availability, (2) a proportion of&#xD;
      children with no or poor response, (3) some issues of long-term compliance (4) the&#xD;
      possibility of a rebound effect after treatment cessation.&#xD;
&#xD;
      Among the non-drug myopia control strategies, corrective lenses including the Defocus&#xD;
      Incorporated Multiple Segments® (DIMS®) technology have demonstrated their effectiveness in a&#xD;
      previous study (Hong Kong) when compared to monofocal lenses.&#xD;
&#xD;
      The aim of this study is to compare the efficacy of DIMS lenses alone versus atropine 0.05%&#xD;
      eyedrops + monofocal lenses, on the evolution of ocular axial length at 2 years in myopic&#xD;
      children.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2021</start_date>
  <completion_date type="Anticipated">October 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Axial length measurements</measure>
    <time_frame>Inclusion, 24 months</time_frame>
    <description>Difference between the mean of 6 axial length measurements (in mm) acquired with the IOLMaster 500® at 24 months and the mean of 6 axial length measurements at inclusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spherical equivalent</measure>
    <time_frame>Pre inclusion (screening consultation in the 15 days preceding inclusion), 24 months</time_frame>
    <description>Difference in spherical equivalent (in diopters) under cycloplegia on autorefractometer at 24 months and at preinclusion</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>DIMS®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Defocus Incorporated Multiple Segments® lenses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-concentration atropine + monofocal lenses</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Defocus Incorporated Multiple Segments® (DIMS®) lenses</intervention_name>
    <description>Daily wear for 24 months. Lenses have a central monofocal optical zone correcting spherical or spherocylindrical ametropia, surrounded by a ring made up of 300 defocusing pellets. This lens geometry reduces the phenomenon of blurred image projected in the retinal periphery, encountered when myopic eyes are corrected with monofocal lenses.</description>
    <arm_group_label>DIMS®</arm_group_label>
    <other_name>Miyosmart®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atropine 0.05% eyedrops</intervention_name>
    <description>One drop each evening in both eyes for 24 months.</description>
    <arm_group_label>Low-concentration atropine + monofocal lenses</arm_group_label>
    <other_name>Low-concentration atropine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Monofocal lenses</intervention_name>
    <description>Daily wear for 24 months</description>
    <arm_group_label>Low-concentration atropine + monofocal lenses</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of myopia - measured under cycloplegia - defined by:&#xD;
&#xD;
               1. A sphere power between -1 and -6 Diopters, on at least one of the two eyes&#xD;
&#xD;
               2. AND a cylindrical power strictly inferior to 2 Diopters&#xD;
&#xD;
               3. AND a maximum refractive error strictly inferior to 8 Diopters in the flattest&#xD;
                  axis&#xD;
&#xD;
          -  Not benefiting and never having benefited from a myopia control strategy&#xD;
             (orthokeratology, soft defocusing lenses, low concentration atropine eye drops,&#xD;
             peripheral defocusing corrective lenses)&#xD;
&#xD;
          -  Written consent of both parents&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of genetic disease, or general condition suggesting a syndromic myopia&#xD;
             (including an axial length greater than 27 mm)&#xD;
&#xD;
          -  Strabismus&#xD;
&#xD;
          -  Amblyopia defined by a best corrected visual acuity strictly inferior to 10/10 on one&#xD;
             of the two eyes&#xD;
&#xD;
          -  Anisometropia defined by a difference of 2 Diopters or more between the two eyes (in&#xD;
             spherical equivalent)&#xD;
&#xD;
          -  History of allergy to atropine&#xD;
&#xD;
          -  History of severe anaphylaxis&#xD;
&#xD;
          -  Optical correction with contact lenses&#xD;
&#xD;
          -  Previous ophthalmologic surgery of the cornea, lens, retina&#xD;
&#xD;
          -  History of glaucoma or any other chronic ophthalmological disease in the course of&#xD;
             treatment (including vernal keratoconjunctivitis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles MARTIN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Fondation Adolphe de Rothschild</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amélie YAVCHITZ, MD</last_name>
    <phone>+33148036433</phone>
    <email>ayavchitz@for.paris</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gilles MARTIN, MD</last_name>
    <email>gmartin@for.paris</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Fondation Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles MARTIN</last_name>
      <email>gmartin@for.paris</email>
    </contact>
    <contact_backup>
      <last_name>Pauline BEAUJEUX</last_name>
      <email>pbeaujeux@for.paris</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myopia</keyword>
  <keyword>Pediatric ophthalmology</keyword>
  <keyword>Myopia control</keyword>
  <keyword>Defocus Incorporated Multiple Segments (DIMS) lenses</keyword>
  <keyword>Low concentration atropine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atropine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

